Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Appointed director
CC transcript
Inv. presentation
VIROPHARMA INC (VPHM) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/24/2014 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "Fourth Amended and Restated Certificate of Incorporation of ViroPharma Incorporated, amended as of January 24, 2014",
"Amended and Restated By-Laws of ViroPharma Incorporated, amended as of January 24, 2014"
11/14/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Notice to Holders of ViroPharma Incorporated 2.00% Convertible Senior Notes due 2017"
11/12/2013 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, among ViroPharma Incorporated, Shire Pharmaceutical Holdings Ireland Limited, Venus Newco, Inc. and Shire plc",
"www.shire.com Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects Earnings accretive, revenue growth-enhancing acquisition Dublin, Ireland and Exton, PA, US — November 11, 2013 — Shire plc and ViroPharma Incorporated today announce that their Boards of Directors have unanimously approved, and the companies have entered into, a merger agreement pursuant to which Shire will acquire all the outstanding shares of the rare disease company ViroPharma for $50 per share in cash, for a total consideration of approximately $4.2 billion. The $50 per share price in the transaction represents a 27% premium to ViroPharma's closing share price on Friday, November 8, 2013, the last trading day prior to announcement, and a 64% pre..."
10/31/2013 8-K Quarterly results
09/03/2013 8-K Other Events
08/01/2013 8-K Quarterly results
Docs: "VIROPHARMA Announces Second Quarter 2013 Financial Results",
"VIROPHARMA PROVIDES UPDATE ON PHASE 2 CLINICAL EVALUATION OF SUBCUTANEOUS CINRYZE®"
06/27/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "VIROPHARMA PROVIDES UPDATE FROM ONGOING PHASE 2 STUDIES OF MARIBAVIR FOR TREATMENT OF CYTOMEGALOVIRUS INFECTIONS"
04/22/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Detection of NTCD in stool and rates of CDI recurrence, Antibacterial Use for CDI Treatment and Clinical Diarrhea Events; Placebo vs. VP20621 VP20621 Placebo 104 x 7d 107 x 7d 107 x 14d All VP20621 doses n 43 41 43 41 125 NTCD detected in stool during 14 day administration period 0 % 54 % 79 % 73 % 69 % p value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 CDI Recurrence 30 % 15 % 5 % 15 % 11 % p value vs. placebo 0.11 <0.01 0.10 <0.01 Antibacterial Use for CDI Treatment 33 % 15 % 9 % 17 % 14 % p value vs. placebo 0.06 0.02 0.14 <0.01 Event of diarrhea or loose stool of any severity or duration 77 % 56 % 58 % 56 % 57 % p value vs. placebo 0.05 0.09 0.02 0.02 Safety: VP20621 exhibited a favorable tolerability profile:"
03/19/2013 8-K Entry into a Material Definitive Agreement
03/05/2013 8-K Other Events
02/27/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "VIROPHARMA Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results - Company Delivers Record Full Year Worldwide Cinryze® Net Sales of $327 Million -"
01/07/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VIROPHARMA PROVIDES 2013 OUTLOOK - Provides 2013 Annual Net Sales Guidance of Up to $475 Million -"
10/25/2012 8-K Quarterly results
Docs: "VIROPHARMA Incorporated Reports Third Quarter 2012 Financial Results - Quarter Highlighted by Record U.S. Cinryze ® Net Sales of $83.7M; Company Reiterates Cinryze U.S. Net Sales Guidance -"
10/03/2012 8-K Entry into a Material Definitive Agreement
09/25/2012 8-K Form 8-K - Current report
08/31/2012 8-K Entry into a Material Definitive Agreement
08/22/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2012 8-K Quarterly results
Docs: "VIROPHARMA Incorporated Reports Second Quarter 2012 Financial Results - Increases 2012 U.S. Cinryze ® Net Product Sales Guidance to between $320 and $335 Million -"
08/06/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "VIROPHARMA RECEIVES FDA APPROVAL OF CINRYZE ® INDUSTRIAL SCALE MANUFACTURING - Financial Results expected to be released on Thursday, August 9th at 7:30 AM ET -"
08/01/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "ViroPharma Provides Update on Phase 2 Clinical Evaluation of Subcutaneous Cinryze ® with Recombinant Human Hyaluronidase"
06/22/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/23/2012 8-K Form 8-K - Current report
05/18/2012 8-K Other Events
05/01/2012 8-K Quarterly results
Docs: "VIROPHARMA Incorporated Reports First Quarter 2012 Financial Results"
04/24/2012 8-K Form 8-K - Current report
04/10/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "VIROPHARMA PROVIDES UPDATE ON STATUS OF CITIZEN PETITION REGARDING BIOEQUIVALENCE AND EXCLUSIVITY FOR VANCOCIN® CAPSULES"
03/02/2012 8-K Form 8-K - Current report
01/06/2012 8-K Form 8-K - Current report
01/05/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VIROPHARMA PROVIDES 2012 OUTLOOK - Provides 2012 Annual Net Sales Guidance of Up to $660 Million -"
01/04/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "VIROPHARMA ANNOUNCES APPOINTMENT OF JULIE H. MCHUGH TO BOARD OF DIRECTORS",
"ViroPharma supplement to its citizen petition regarding Vancocin"
12/23/2011 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "VIROPHARMA PURCHASES EXCLUSIVE OPTION TO ACQUIRE MERITAGE PHARMA - Option Creates Opportunity to Further Augment Rare Disease Development Pipeline with Novel Orphan Drug for Eosinophilic Esophagitis, a Chronic Inflammatory Disease -"
12/14/2011 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "VIROPHARMA ANNOUNCES APPROVAL OF MODERNIZED LABELING FOR VANCOCIN ® CAPSULES - Modernized Label Provides Safety and Efficacy Data Based on Clinical Studies - - Company Provides Citizen Petition and Litigation Updates -"
12/06/2011 8-K Form 8-K - Current report
11/15/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy